Sarah Ross

5PUBLICATIONS
103CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Nov 25, 2025
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.

Mark White, Megan L Mills, Laura M Millett

|Oct 24, 2022
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer.

Hajrah Khawaja, Rebecca Briggs, Cheryl H Latimer

|Aug 05, 2022
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.

Jesse Boumelha, Sophie de Carné Trécesson, Emily K Law

|Aug 05, 2022
AZD4625 is a Potent and Selective Inhibitor of KRASG12C.

Atanu Chakraborty, Lyndsey Hanson, David Robinson

|Jun 16, 2017
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

Sarah J Ross, Alexey S Revenko, Lyndsey L Hanson

Pageof 1